$5.10
Manufacturer: India
Antiallergic agent – H 1 -histamine receptor blocker. ATX code: R06AE09
Allervei 5 mg film-coated tablets are indicated to adults and children 6 years of age and older with:
- treatment of symptoms of allergic rhinitis, including year-round (persistent) and seasonal (intermittent) allergic rhinitis, and allergic conjunctivitis, such as itching, sneezing, nasal congestion, rhinorrhea, lacrimation, conjunctival hyperemia;
- pollinosis (hay fever);
- urticaria;
- other allergic dermatoses, accompanied by itching and rashes.
Description
Composition
Each film-coated tablet contains:
active ingredient: levocetirizine dihydrochloride 5.00 mg;
excipients: lactose monohydrate 88.00 mg; cellulose microcrystalline 34.10 mg; colloidal silicon dioxide 1.60 mg; magnesium stearate 1.30 mg;
film casing: Opadry white OY-58900 (hypromellose (5 cP) 62.5%, titanium dioxide (E171) 31.25%, macrogol-400 6.25%) 3.25 mg.
Pharmacotherapeutic group:
antiallergic agent – H 1 -histamine receptor blocker.
ATX code: R06AE09
Pharmacodynamics
Levocetirizine (R)-enantiomer of cetirizine, is an inhibitor of peripheral H 1 histamine receptors.
Levocetirizine has a pronounced antihistamine and antiallergic effect. It affects the histamine-dependent phase of the allergic reaction, reduces the migration of eosinophils, reduces the permeability of the vascular wall and limits the release of inflammatory mediators.
Levocetirizine prevents the development and facilitates the course of allergic reactions, has antipruritic and antiexudative action. It practically does not affect cholinergic and serotonin receptors, in therapeutic doses it does not have a sedative effect.
Indications for use
Allervei 5 mg film-coated tablets are indicated to adults and children 6 years of age and older with:
- treatment of symptoms of allergic rhinitis, including year-round (persistent) and seasonal (intermittent) allergic rhinitis, and allergic conjunctivitis, such as itching, sneezing, nasal congestion, rhinorrhea, lacrimation, conjunctival hyperemia;
- pollinosis (hay fever);
- urticaria;
- other allergic dermatoses, accompanied by itching and rashes.
Contraindications
- Hypersensitivity to the active substance, cetirizine, hydroxyzine, any piperazine derivative or any excipient of the drug.
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
- End-stage renal failure (CC < 10 ml / min).
- Children under 6 years of age (due to limited data on safety and efficacy).
Carefully
- In chronic renal failure (correction of the dosing regimen is necessary).
- In elderly patients (with an age-related decrease in glomerular filtration).
- In patients with spinal cord injury, prostatic hyperplasia, and in the presence of other predisposing factors for urinary retention, since levocetirizine may increase the risk of urinary retention.
- With simultaneous use with alcohol.
- When administered to pregnant women and during breastfeeding.
Dosage and administration
Allervei (levocetirizine) should be taken orally, without chewing and with liquid, regardless of the meal.
Adults and children over 6 years old
The daily dose is 5 mg (1 tablet) once.
Duration of taking the drug
In the treatment of seasonal (intermittent) rhinitis (presence of symptoms less than 4 days a week or their total duration less than 4 weeks), the duration of treatment depends on the duration of the symptoms; treatment can be stopped when symptoms disappear and resumed when symptoms appear.
In the treatment of year-round (persistent) allergic rhinitis (presence of symptoms more than 4 days a week and their total duration of more than 4 weeks), treatment can continue during the entire period of exposure to allergens.
The course of treatment for hay fever is determined by the doctor.
There is clinical experience with continuous use of Allervei (levocetirizine) in adult patients for up to 6 months. If you miss a dose, do not take a double dose, take the next dose at the usual time.
Recent Reviews